Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomerica (BMRA) EBITDA (2016 - 2025)

Biomerica's EBITDA history spans 16 years, with the latest figure at -$1.3 million for Q4 2025.

  • For Q4 2025, EBITDA fell 38.47% year-over-year to -$1.3 million; the TTM value through Nov 2025 reached -$4.0 million, up 28.43%, while the annual FY2025 figure was -$5.0 million, 16.65% up from the prior year.
  • EBITDA for Q4 2025 was -$1.3 million at Biomerica, down from $4000.0 in the prior quarter.
  • Across five years, EBITDA topped out at $4000.0 in Q3 2025 and bottomed at -$2.1 million in Q1 2021.
  • The 5-year median for EBITDA is -$1.5 million (2023), against an average of -$1.4 million.
  • The largest annual shift saw EBITDA crashed 1460.36% in 2023 before it surged 100.3% in 2025.
  • A 5-year view of EBITDA shows it stood at -$1.1 million in 2021, then crashed by 44.69% to -$1.6 million in 2022, then grew by 7.83% to -$1.5 million in 2023, then soared by 36.7% to -$954000.0 in 2024, then tumbled by 38.47% to -$1.3 million in 2025.
  • Per Business Quant, the three most recent readings for BMRA's EBITDA are -$1.3 million (Q4 2025), $4000.0 (Q3 2025), and -$1.5 million (Q2 2025).